"","Column1","study","year","psy_or_med","active_type","control_type","descr_active","descr_control","instrument","instrument_value","rating","baseline_mean_active","baseline_sd_active","baseline_n_active","baseline_mean_control","baseline_sd_control","baseline_n_control","post_mean_active","post_sd_active","post_n_active","post_mean_control","post_sd_control","post_n_control","active_mean_change","active_sd_change","active_n_change","control_mean_change","control_sd_change","control_n_change","response_criterion","observed_responders_active","observed_responders_active_n","observed_resp_rate_active","observed_responders_control","observed_responders_control_n","observed_resp_rate_control","responders_active","responders_control","resp_rate_active","resp_rate_control","resp_rate_active_completers","resp_rate_control_completers","...1","cuij_responders_active","cuij_responders_control","time_weeks","comorbid_mental","comorbid_mental?","country","age_group","mean_age","active_mean_age","control_mean_age","percent_women","active_percent_women","control_percent_women","diagnosis","Notes","cohens_d_active","cohens_d_control"
"1",1,"Organon","2002a",0,"Mirtazapine","Placebo",NA,NA,"CDRS",1,"clinician",NA,NA,82,NA,NA,44,35.08,NA,82,37.24,NA,44,NA,NA,NA,NA,NA,NA,"missing",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,"n","NA",NA,"7 to 17",NA,12.3,12.4,NA,47.6,56.8,"mdd","FDA trial - poor reporting",NA,NA
"2",2,"Organon","2002b",0,"Mirtazapine","Placebo",NA,NA,"CDRS",1,"clinician",NA,NA,85,NA,NA,45,35.39,NA,82,38.76,NA,41,NA,NA,NA,NA,NA,NA,"missing",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,"n","NA",NA,"7 to 17",NA,11.9,12.3,NA,50,50.5,"mdd",NA,NA,NA
"3",3,"Atkinson","2014.0",0,"Duloxetine","Placebo",NA,NA,"CDRS-R",1,"clinician",59.2,10.5,117,60.2,11.7,103,35,NA,87,35,NA,87,NA,NA,NA,NA,NA,NA,"50% improvement on CDRS",NA,NA,0.67,NA,NA,0.62,NA,NA,NA,NA,NA,NA,NA,NA,NA,10,"n","NA","USA","7 to 17",NA,13.1,13.1,NA,54.7,49.5,"mdd",NA,NA,NA
"4",4,"Atkinson","2014.0",0,"Fluoxetine","Placebo",NA,NA,"CDRS-R",1,"clinician",58.8,10.6,117,60.2,11.7,103,35.6,NA,91,35,NA,87,NA,NA,NA,NA,NA,NA,"50% improvement on CDRS",NA,NA,0.63,NA,NA,0.62,NA,NA,NA,NA,NA,NA,NA,NA,NA,10,"n","NA","USA","7 to 17",NA,13.1,13.1,NA,52.1,49.5,"mdd",NA,NA,NA
"5",5,"Berard","2006.0",0,"Paroxetine","Placebo",NA,NA,"MADRS",3,"clinician",25.9,6.75,182,25.9,5.79,93,NA,NA,177,NA,NA,177,-13.6,10.91,177,-12.8,10.3,91,"50% improvement from baseline",107,177,0.604519774011299,53,91,0.582417582417582,NA,NA,NA,NA,NA,NA,NA,NA,NA,12,"y","Anxiety disorders (specific phobia, separation anxiety disorder, panic disorder, social phobia, GAD) and ADHD","International (Belgium, Italy, Spain, UK< The Netherlands, Canada, South Africa, UAE, Argentina, Mexico)","12 to 19",NA,15.5,15.8,NA,67,67,"mdd",NA,NA,NA
"6",6,"Berard","2006.0",0,"Paroxetine","Placebo",NA,NA,"K-SADS-L",6,"clinician",NA,NA,182,NA,NA,93,NA,NA,171,NA,NA,88,-9.33,7.06,171,-8.92,6.57,88,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,12,"y","Anxiety disorders (specific phobia, separation anxiety disorder, panic disorder, social phobia, GAD) and ADHD","International (Belgium, Italy, Spain, UK< The Netherlands, Canada, South Africa, UAE, Argentina, Mexico)","12 to 19",NA,15.5,15.8,NA,67,67,"mdd",NA,NA,NA
"7",7,"Berard","2006.0",0,"Paroxetine","Placebo",NA,NA,"CGI-I",99,"clinician",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CGI scale improvement rating of 1 or 2",119,172,0.691860465116279,51,89,0.573033707865168,NA,NA,NA,NA,NA,NA,NA,NA,NA,12,"y","Anxiety disorders (specific phobia, separation anxiety disorder, panic disorder, social phobia, GAD) and ADHD","International (Belgium, Italy, Spain, UK< The Netherlands, Canada, South Africa, UAE, Argentina, Mexico)","12 to 19",NA,15.5,15.8,NA,67,67,"mdd",NA,NA,NA
"8",8,"Berard","2006.0",0,"Paroxetine","Placebo",NA,NA,"BDI",4,"clinician",23,10.79,182,22.4,11.57,93,NA,NA,174,NA,NA,174,-12.5,10.82,174,-12.07,10.25,90,"Change from baseline BDI score.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,12,"y","Anxiety disorders (specific phobia, separation anxiety disorder, panic disorder, social phobia, GAD) and ADHD","International (Belgium, Italy, Spain, UK< The Netherlands, Canada, South Africa, UAE, Argentina, Mexico)","12 to 19",NA,15.5,15.8,NA,67,67,"mdd",NA,NA,NA
"9",9,"Bristol-Myers Squibb","2002a",0,"Nefazodone","Placebo",NA,NA,"CDRS",1,"clinician",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,-25.8,NA,NA,-22.1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,"missing","missing","USA","missing",NA,NA,NA,NA,NA,NA,"mdd","FDA Trial - Poor reporting",NA,NA
"10",10,"Bristol-Myers Squibb","2002a",0,"Nefazodone","Placebo",NA,NA,"HAM-D",2,"clinician",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,-9.9,NA,NA,-8,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,"missing","missing","USA","missing",NA,NA,NA,NA,NA,NA,"mdd",NA,NA,NA
"11",11,"Bristol-Myers Squibb","2002a",0,"Nefazodone","Placebo",NA,NA,"CGI-I",99,"clinician",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CGI scale improvement rating of 1 or 2",NA,NA,0.63,NA,NA,0.44,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,"missing","missing","USA","missing",NA,NA,NA,NA,NA,NA,"mdd",NA,NA,NA
"12",12,"Bristol-Myers Squibb","2002b",0,"Nefazodone","Placebo",NA,NA,"CDRS",1,"clinician",61.2,NA,90,58.3,NA,93,NA,NA,NA,NA,NA,NA,-23.2,NA,90,-21.6,NA,93,"missing",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,"missing","missing","USA","missing",NA,NA,NA,NA,NA,NA,"mdd",NA,NA,NA
"13",13,"Emslie","1997.0",0,"Fluoxetine","Placebo",NA,NA,"CDRS",1,"clinician",58.5,10.5,48,57.6,10.4,48,38.4,14.8,34,47.1,17,26,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,4,0.2708,0.0833,0.3824,0.1538,NA,NA,NA,8,"y","Dysthymia, anxiety disordes, ADHD, oppositional/conduct disorder","USA","7 to 17",NA,12.2,12.5,NA,46,46,"mdd",NA,-1.58893280632411,-0.766423357664234
"14",14,"Emslie","1997.0",0,"Fluoxetine","Placebo",NA,NA,"CDI/BDI *",99,"clinician",15.8,10.6,48,15.3,11.9,48,9.9,12,34,11.2,10.8,26,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,10,7,0.2083,0.1458,0.2941,0.2692,NA,NA,NA,8,"y","Dysthymia, anxiety disordes, ADHD, oppositional/conduct disorder","USA","7 to 17",NA,12.2,12.5,NA,46,46,"mdd","*For CDI and BDI Baseline/post-test measures were reported together: CDI/BDI, baseline 15.8, post-test 9.9. But only children (≤12yo) completed the CDI and only adolescents (≥13yo) completed the BDI",-0.52212389380531,-0.361233480176212
"15",15,"Emslie","1997.0",0,"Fluoxetine","Placebo",NA,NA,"CGI-I",99,"clinician",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CGI scale improvement rating of 1 or 2",27,48,0.5625,16,48,0.333333333333333,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,"y","Dysthymia, anxiety disordes, ADHD, oppositional/conduct disorder","USA","7 to 17",NA,12.2,12.5,NA,46,46,"mdd",NA,NA,NA
"16",16,"Emslie","2002a",0,"Fluoxetine","Placebo",NA,NA,"CDRS",1,"clinician",57.1,9.9,109,55.1,11.8,110,35.1,13.5,109,40.2,13.5,105,NA,NA,NA,NA,NA,NA,"30% improvement in CDRS",71,109,0.651376146788991,54,101,0.534653465346535,29,20,0.2661,0.1818,0.2661,0.1905,NA,NA,NA,9,"y","ADHD, oppositional defiant disorder, conduct disorder","USA","8 to 17",NA,12.7,12.7,NA,49.5,49.5,"mdd",NA,-1.88034188034188,-1.17786561264822
"17",17,"Emslie","2002a",0,"Fluoxetine","Placebo",NA,NA,"MADRS",3,"clinician",21.6,7.5,109,21.5,8.3,110,11.2,9,109,13.9,8.2,105,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,52,39,0.4771,0.3545,0.4771,0.3714,NA,NA,NA,9,"y","ADHD, oppositional defiant disorder, conduct disorder","USA","8 to 17",NA,12.7,12.7,NA,49.5,49.5,"mdd",NA,-1.26060606060606,-0.921212121212121
"18",18,"Emslie","2002a",0,"Fluoxetine","Placebo",NA,NA,"CGI-I",99,"clinician",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CGI scale improvement rating of 1 or 2",57,109,0.522935779816514,NA,NA,0.368,NA,NA,NA,NA,NA,NA,NA,NA,NA,9,"y","ADHD, oppositional defiant disorder, conduct disorder","USA","8 to 17",NA,12.7,12.7,NA,49.5,49.5,"mdd",NA,NA,NA
"19",19,"Emslie","2002b",0,"Nefazadone","Placebo",NA,NA,"CDRS",1,"clinician",NA,NA,99,NA,NA,96,NA,NA,99,NA,NA,96,-26.5,NA,99,-22.5,NA,96,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,"missing","NA","USA","12 to 17",NA,NA,NA,NA,NA,NA,"mdd",NA,NA,NA
"20",20,"Emslie","2002b",0,"Nefazadone","Placebo",NA,NA,"HAM-D",2,"clinician",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,-10,NA,99,-8.2,NA,96,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,"missing","NA","USA","12 to 17",NA,NA,NA,NA,NA,NA,"mdd",NA,NA,NA
"21",21,"Emslie","2002b",0,"Nefazadone","Placebo",NA,NA,"CGI-I",99,"clinician",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CGI scale improvement rating of 1 or 2",61,99,0.616161616161616,40,96,0.416666666666667,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,"missing","NA","USA","12 to 17",NA,NA,NA,NA,NA,NA,"mdd",NA,NA,NA
"22",22,"Emslie","2006.0",0,"Paroxetine","Placebo",NA,NA,"CDRS",1,"clinician",60.7,9.37,101,62.6,8.96,102,NA,NA,101,NA,NA,100,-22.58,1.47,101,-23.38,1.6,100,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,"y","adhd","USA + Canada","7 to 17",NA,12,12,NA,46.8,46.8,"mdd","adhd was the most prevalent psychiatric condition, but others were not listed.",NA,NA
"23",23,"Emslie","2006.0",0,"Paroxetine","Placebo",NA,NA,"CGI-I",99,"clinician",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CGI scale improvement rating of 1 or 2",49,101,0.485148514851485,46,100,0.46,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,"y","adhd","USA + Canada","7 to 17",NA,12,12,NA,46.8,46.8,"mdd",NA,NA,NA
"24",24,"Emslie","2007a",0,"Venlafaxine ER","Placebo",NA,NA,"CDRS",1,"clinician",54.4,NA,80,54.4,NA,85,36.3,13.19,68,38.3,12.82,73,NA,NA,NA,NA,NA,NA,"35% improvement from baseline score",43,68,0.632352941176471,37,73,0.506849315068493,22,15,0.275,0.1765,0.3235,0.2055,NA,NA,NA,8,"n","NA","USA","7 to 17",NA,NA,NA,NA,NA,NA,"mdd","*In this study, there were two trials (two groups of fluox, two groups of placebo). CDRS scores were reported per trial (fluox v placebo; fluox v placebo)",NA,NA
"25",25,"Emslie","2007b",0,"Venlafaxine ER","Placebo",NA,NA,"CDRS",1,"clinician",57.3,NA,102,57.3,NA,94,32.7,13.06,101,34.5,13.43,92,NA,NA,NA,NA,NA,NA,"35% improvement from baseline score",77,101,0.762376237623762,62,92,0.673913043478261,30,32,0.2941,0.3404,0.297,0.3478,NA,NA,NA,8,"n","NA","USA","7 to 17",NA,NA,NA,NA,NA,NA,"mdd","*Did not report demographics (e.g. mean age, % of women) per trial. Instead, demographics were reported for the two trials combined, hence the (combined)",NA,NA
"26",26,"Emslie","2007 (combined)",0,"Venlafaxine ER","Placebo",NA,NA,"MADRS",3,"clinician",25.6,6.6,168,25.1,6.1,169,NA,NA,160,NA,NA,161,NA,NA,NA,NA,NA,NA,"50% improvement from baseline score",81,160,0.50625,75,161,0.46583850931677,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,"n","NA","USA","7 to 17",NA,12.2,12.3,NA,44,47,"mdd","*Did not report secondary outcome measures per trial. Instead they reported MADRS & HAM-D scores for the combined population, hence why n is larger.",NA,NA
"27",27,"Emslie","2007 (combined)",0,"Venlafaxine ER","Placebo",NA,NA,"HAM-D",2,"clinician",18.2,5.6,168,18.1,5.6,169,NA,NA,166,NA,NA,162,NA,NA,NA,NA,NA,NA,"50% improvement from baseline score",85,166,0.512048192771084,79,162,0.487654320987654,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,"n","NA","USA","7 to 17",NA,12.2,12.3,NA,44,47,"mdd",NA,NA,NA
"28",28,"Emslie","2009.0",0,"Escitalopram","Placebo",NA,NA,"CDRS",1,"clinician",57.6,8.19,154,56,8.27,157,NA,NA,NA,NA,NA,NA,-22.1,15.14,154,-18.8,15.91,157,"40% improvement from baseline score",91,154,0.590909090909091,76,157,0.484076433121019,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,"y","ADHD, enuresis, GAD","USA","12 to 17",NA,14.7,14.5,NA,59.4,58.6,"mdd","Has two response criteria (40% improvement, and CGI-I)",NA,NA
"29",29,"Emslie","2009.0",0,"Escitalopram","Placebo",NA,NA,"CGI-I",99,"clinician",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CGI scale improvement rating of 1 or 2",99,154,0.642857142857143,83,157,0.528662420382166,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,"y","ADHD, enuresis, GAD","USA","12 to 17",NA,14.7,14.5,NA,59.4,58.6,"mdd",NA,NA,NA
"30",30,"Emslie","2014.0",0,"Duloxetine","Placebo",NA,NA,"CDRS",1,"clinician",59.3,10.9,108,58.2,9.4,122,35,NA,105,37.4,NA,117,-23.9,NA,105,-21.6,NA,117,"50% improvement from baseline scores",NA,NA,0.69,NA,NA,0.6,NA,NA,NA,NA,NA,NA,NA,NA,NA,10,"n","NA","USA, Mexico, Canada, Argentina","7 to 17",NA,12.9,13.1,NA,55.6,56.6,"mdd","*Had four conditions (duloxetine 60mg, duloxetine 30mg, fluoxetine 20mg, placebo)",NA,NA
"31",31,"Emslie","2014.0",0,"Duloxetine","Placebo",NA,NA,"CDRS",1,"clinician",59.8,11,116,58.2,9.4,122,34.4,NA,114,37.4,NA,117,-24.6,NA,114,-21.6,NA,117,"50% improvement from baseline scores",NA,NA,0.69,NA,NA,0.6,NA,NA,NA,NA,NA,NA,NA,NA,NA,10,"n","NA","USA, Mexico, Canada, Argentina","7 to 17",NA,12.9,13.1,NA,40.5,56.6,"mdd",NA,NA,NA
"32",32,"Emslie","2014.0",0,"Fluoxetine","Placebo",NA,NA,"CDRS",1,"clinician",57.9,10.1,117,58.2,9.4,122,36.4,NA,112,37.4,NA,117,22.6,NA,112,-21.6,NA,117,"50% improvement from baseline scores",NA,NA,0.61,NA,NA,0.6,NA,NA,NA,NA,NA,NA,NA,NA,NA,10,"n","NA","USA, Mexico, Canada, Argentina","7 to 17",NA,13,13.1,NA,52.1,56.6,"mdd",NA,NA,NA
"33",33,"Findling","2009.0",0,"Fluoxetine","Placebo",NA,NA,"CDRS",1,"clinician",53,9.84,18,53.94,9.84,16,34.6,13.66,18,31.31,13.68,16,-18.4,12.47,18,-22.63,12.48,16,"30% improvement from baseline",NA,NA,0.72,NA,16,0.81,5,2,0.2778,0.125,0.2778,0.125,NA,NA,NA,8,"y","Substance-related disorder, ADHD, PTSD, conduct disorder","USA","12 to 17",NA,16.55,16.35,NA,22,6,"mdd",NA,-1.56595744680851,-1.92431972789116
"34",34,"Findling","2009.0",0,"Fluoxetine","Placebo",NA,NA,"BDI",4,"self-report",17.2,13.15,18,13,13.32,16,7.62,7.59,15,8.12,7.61,13,-9.58,12.74,15,-4.88,12.76,13,NA,NA,NA,NA,NA,NA,NA,7,8,0.3889,0.5,0.4667,0.6154,NA,NA,NA,8,"y","Substance-related disorder, ADHD, PTSD, conduct disorder","USA","12 to 17",NA,16.55,16.35,NA,22,6,"mdd",NA,-0.923818707810993,-0.466316292403249
"35",35,"Findling","2009.0",0,"Fluoxetine","Placebo",NA,NA,"CGI-I",99,"clinician",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CGI scale improvement rating of 1 or 2",9,18,0.5,6,16,0.375,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,"y","Substance-related disorder, ADHD, PTSD, conduct disorder","USA","12 to 17",NA,16.55,16.35,NA,22,6,"mdd",NA,NA,NA
"36",36,"Geller","1990.0",0,"Nortriptyline","Placebo",NA,NA,"GAS",99,"clinician",37.6,3.8,12,38.6,3.9,19,54.2,14.9,12,48.9,16.2,19,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,NA,NA,NA,8,"y","Melancholia, separation anxiety, antisocial behaviour","USA","12 to 17",NA,14.3,14.3,NA,75,42.1,"mdd",NA,1.77540106951872,1.02487562189055
"37",37,"Geller","1990.0",0,"Nortriptyline","Placebo",NA,NA,"CDRS",1,"clinician",51.3,4.4,12,52.4,3.7,19,34.7,7.8,12,37.8,9.1,19,NA,NA,NA,NA,NA,NA,"CDRS score of ≤25",1,12,0.0833333333333333,4,19,0.210526315789474,2,2,0.1667,0.1053,0.1667,0.1053,NA,NA,NA,8,"y","Melancholia, separation anxiety, antisocial behaviour","USA","12 to 17",NA,14.3,14.3,NA,75,42.1,"mdd",NA,-2.72131147540984,-2.28125
"38",38,"Geller","1992.0",0,"Nortriptyline","Placebo",NA,NA,"CDRS",1,"clinician",49.9,4.2,26,49.6,4.6,24,32.9,11.4,26,32,9.8,24,NA,NA,NA,NA,NA,NA,"CDRS score of ≤20",8,26,0.307692307692308,4,24,0.166666666666667,6,4,0.2308,0.1667,0.2308,0.1667,NA,NA,NA,8,"n","NA","USA","6 to 12",NA,9.7,9.7,NA,26.9,33.3,"mdd",NA,-2.17948717948718,-2.44444444444444
"39",39,"Geller","1992.0",0,"Nortriptyline","Placebo",NA,NA,"K-SADS-L",6,"clinician",3.98,0.42,26,3.89,0.5,24,2.41,0.81,26,2.2,0.78,24,NA,NA,NA,NA,NA,NA,"Scores of 1 or 2 on all MDD items on the K-SADS",12,26,0.461538461538462,14,24,0.583333333333333,7,9,0.2692,0.375,0.2692,0.375,NA,NA,NA,8,"n","NA","USA","6 to 12",NA,9.7,9.7,NA,26.9,33.3,"mdd",NA,-2.55284552845528,-2.640625
"40",40,"Hughes","1990.0",0,"Imipramine","Placebo",NA,NA,"CDRS",1,"clinician",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"50% reduction in CDRS",4,7,0.571428571428571,1,5,0.2,NA,NA,NA,NA,NA,NA,NA,NA,NA,6,"y","Anxiety-related disorders (Group1) and Conduct or oppositional disorders (group2)",NA,"6 to 12",NA,NA,NA,NA,NA,NA,"mdd",NA,NA,NA
"41",41,"Hughes","1990.0",0,"Imipramine","Placebo",NA,NA,"CDRS",1,"clinician",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"50% reduction in CDRS",2,6,0.333333333333333,6,9,0.666666666666667,NA,NA,NA,NA,NA,NA,NA,NA,NA,6,"y","Anxiety-related disorders (Group1) and Conduct or oppositional disorders (group2)",NA,"6 to 12",NA,NA,NA,NA,NA,NA,"mdd",NA,NA,NA
"42",42,"Keller","2001.0",0,"Paroxetine","Placebo",NA,NA,"HAM-D",2,"clinician",18.98,4.15,93,18.97,4.1,87,8.24,7.68,90,9.88,7.74,87,NA,NA,NA,NA,NA,NA,"50% improvement from baseline",60,90,0.666666666666667,48,87,0.551724137931034,55,44,0.5914,0.5057,0.6111,0.5057,NA,NA,NA,8,"y","Anxiety disorders (e.g. separation anxiety, social anxiety disorder) and externalising disorders","USA + Canada","12 to 18",NA,14.8,15.1,NA,62.4,65.5,"mdd",NA,-1.81572273879966,-1.53547297297297
"43",43,"Keller","2001.0",0,"Paroxetine","Placebo",NA,NA,"K-SADS-L",6,"clinician",28.25,5.01,93,28.84,4.85,87,16.59,7.65,83,19.27,7.65,85,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,32,20,0.3441,0.2299,0.3855,0.2353,NA,NA,NA,8,"y","Anxiety disorders (e.g. separation anxiety, social anxiety disorder) and externalising disorders","USA + Canada","12 to 18",NA,14.8,15.1,NA,62.4,65.5,"mdd",NA,-1.84202211690363,-1.5312
"44",44,"Keller","2001.0",0,"Paroxetine","Placebo",NA,NA,"CGI-I",99,"clinician",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CGI scale improvement rating of 1 or 2",59,90,0.655555555555556,42,87,0.482758620689655,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,"y","Anxiety disorders (e.g. separation anxiety, social anxiety disorder) and externalising disorders","USA + Canada","12 to 18",NA,14.8,15.1,NA,62.4,65.5,"mdd",NA,NA,NA
"45",45,"Keller","2001.0",0,"Imipramine","Placebo",NA,NA,"HAM-D",2,"clinician",18.11,4.19,95,18.97,4.1,87,9.2,7.85,94,9.88,7.74,87,NA,NA,NA,NA,NA,NA,"50% improvement from baseline",55,94,0.585106382978723,48,87,0.551724137931034,46,40,0.4842,0.4598,0.4894,0.4598,NA,NA,NA,8,"y","Anxiety disorders (e.g. separation anxiety, social anxiety disorder) and externalising disorders","USA + Canada","12 to 18",NA,14.9,15.1,NA,58.9,65.5,"mdd",NA,-1.48006644518272,-1.53547297297297
"46",46,"Keller","2001.0",0,"Imipramine","Placebo",NA,NA,"K-SADS-L",6,"clinician",27.54,4.97,95,28.84,4.85,87,17.99,7.79,88,19.27,7.65,85,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,17,0.3158,0.1954,0.3409,0.2,NA,NA,NA,8,"y","Anxiety disorders (e.g. separation anxiety, social anxiety disorder) and externalising disorders","USA + Canada","12 to 18",NA,14.9,15.1,NA,58.9,65.5,"mdd",NA,-1.49686520376176,-1.5312
"47",47,"Keller","2001.0",0,"Imipramine","Placebo",NA,NA,"CGI-I",99,"clinician",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CGI scale improvement rating of 1 or 2",49,94,0.521276595744681,42,87,0.482758620689655,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,"y","Anxiety disorders (e.g. separation anxiety, social anxiety disorder) and externalising disorders","USA + Canada","12 to 18",NA,14.9,15.1,NA,58.9,65.5,"mdd",NA,NA,NA
"48",48,"Klein","1998.0",0,"Desipamine","Placebo",NA,NA,"HAM-D",2,"clinician",21.44,3.7,23,21.33,5.2,22,10.23,2.1,18,14.61,2.1,18,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,1,0.3478,0.0455,0.4444,0.0556,NA,NA,NA,6,"y","Anxiety disorders and behaviour disorders","USA","13 to 18",NA,15.66,15.66,NA,67,67,"mdd",NA,-3.86551724137931,-1.84109589041096
"49",49,"Klein","1998.0",0,"Desipamine","Placebo",NA,NA,"BDI",4,"clinician",24.62,9.4,23,21.57,11.1,22,12,9.6,16,15.92,9.6,14,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,10,5,0.4348,0.2273,0.625,0.3571,NA,NA,NA,6,"y","Anxiety disorders and behaviour disorders","USA","13 to 18",NA,15.66,15.66,NA,67,67,"mdd",NA,-1.32842105263158,-0.545893719806763
"50",50,"Klein","1998.0",0,"Desipamine","Placebo",NA,NA,"CGI-I",99,"clinician",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CGI scale improvement rating of 1 or 2",12,18,0.666666666666667,9,18,0.5,NA,NA,NA,NA,NA,NA,NA,NA,NA,6,"y","Anxiety disorders and behaviour disorders","USA","13 to 18",NA,15.66,15.66,NA,67,67,"mdd",NA,NA,NA
"51",51,"Kutcher","1994.0",0,"Desipramine","Placebo",NA,NA,"HAM-D",2,"clinician",22.63,5.17,30,23.77,5.31,30,12.68,8.68,17,13.42,8.43,25,NA,NA,NA,NA,NA,NA,"50% improvement from baseline",NA,NA,0.48,NA,NA,0.35,9,13,0.3,0.4333,0.5294,0.52,NA,NA,NA,6,"n","NA","Canada","15 to 20",NA,17.8,17.8,NA,70,70,"mdd",NA,-1.43682310469314,-1.50655021834061
"52",52,"Kutcher","1994.0",0,"Desipramine","Placebo",NA,NA,"HAM-D",2,"clinician",22.63,5.17,30,23.77,5.31,30,12.68,8.68,17,13.42,8.43,25,NA,NA,NA,NA,NA,NA,"Dichotomous outcome variable (well/ill). Final HAM-D score of 7 or less indicated well",NA,NA,0.28,NA,NA,NA,7,12,0.2333,0.4,0.4118,0.48,NA,NA,NA,6,"n","NA","Canada","15 to 20",NA,17.8,17.8,NA,70,70,"mdd",NA,-1.43682310469314,-1.50655021834061
"53",53,"Kutcher","1994.0",0,"Desipramine","Placebo",NA,NA,"BDI",4,"self-report",NA,NA,30,NA,NA,30,13.3,NA,17,17.2,NA,25,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,6,"n","NA","Canada","15 to 20",NA,17.8,17.8,NA,70,70,"mdd",NA,NA,NA
"54",54,"Kye","1996.0",0,"Amitriptyline","Placebo",NA,NA,"K-SADS-L",6,"clinician",20.7,4.3,18,18.7,2.2,13,15.7,5.3,12,15.6,4.7,10,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,0,0.1111,0,0.1667,0,NA,NA,NA,8,"n","NA","USA","12 to 17",NA,14.6,15.1,NA,27.7,30.8,"mdd",NA,-1.04166666666667,-0.898550724637681
"55",55,"Kye","1996.0",0,"Amitriptyline","Placebo",NA,NA,"HAM-D",2,"clinician",12,4.5,18,13.2,4.1,13,8,4.9,12,8.8,4.5,10,NA,NA,NA,NA,NA,NA,"50% improvement",13,18,0.722222222222222,11,13,0.846153846153846,7,5,0.3889,0.3846,0.5833,0.5,NA,NA,NA,8,"n","NA","USA","12 to 17",NA,14.6,15.1,NA,27.7,30.8,"mdd",NA,-0.851063829787234,-1.02325581395349
"56",56,"March","2004.0",0,"Fluoxetine","Placebo",NA,NA,"CDRS",1,"clinician",58.94,4,109,61.18,4.27,112,36.3,8.18,109,41.77,7.99,112,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,6,0.156,0.0536,0.156,0.0536,NA,NA,NA,12,"y","Anxiety, disruptive behaviour, obsessive-compulsice/tic, substance use, attention-deficit/hyperactivity","USA","12 to 17",NA,14.6,14.6,NA,54.4,54.4,"mdd",NA,-3.7175697865353,-3.16639477977161
"57",57,"March","2004.0",0,"Fluoxetine","Placebo",NA,NA,"RADS",8,"clinician",76.96,9.57,109,81.26,9.22,112,60.58,13.07,109,66.68,11.41,112,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,7,0,0.0642,0,0.0642,0,NA,NA,NA,12,"y","Anxiety, disruptive behaviour, obsessive-compulsice/tic, substance use, attention-deficit/hyperactivity","USA","12 to 17",NA,14.6,14.6,NA,54.4,54.4,"mdd",NA,-1.4469964664311,-1.4134755210858
"58",58,"March","2004.0",0,"Fluoxetine","Placebo",NA,NA,"CGI-I",99,"clinician",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CGI scale improvement rating of 1 or 2",66,109,0.605504587155963,39,112,0.348214285714286,NA,NA,NA,NA,NA,NA,NA,NA,NA,12,"y","Anxiety, disruptive behaviour, obsessive-compulsice/tic, substance use, attention-deficit/hyperactivity","USA","12 to 17",NA,14.6,14.6,NA,54.4,54.4,"mdd",NA,NA,NA
"59",59,"Paxil (GlaxoSmithKline)","2009.0",0,"Paroxetine","Placebo",NA,NA,"CDRS",1,"clinician",NA,NA,29,NA,NA,27,NA,NA,29,NA,NA,27,-16.5,2.45,29,-11.9,2.54,27,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,"n","NA","Japan","7 to 17",NA,14.4,14.8,NA,55.2,66.7,"mdd",NA,NA,NA
"60",60,"Paxil (GlaxoSmithKline)","2009.0",0,"Paroxetine","Placebo",NA,NA,"CGI-I",99,"clinician",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CGI scale improvement rating of 1 or 2",15,29,0.517241379310345,11,27,0.407407407407407,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,"n","NA","Japan","7 to 17",NA,14.4,14.8,NA,55.2,66.7,"mdd",NA,NA,NA
"61",61,"Puig-Antich","1987.0",0,"Imipramine","Placebo",NA,NA,"K-SADS-L",6,"clinician",3.1,0.43,20,3,0.66,22,1.9,0.68,16,1.9,0.86,22,NA,NA,NA,NA,NA,NA,"Responder: if K-SADS scores in both depressed mood and anhedonia were ≤2. Non-responder: if K-SADS score for at least one of these two key items were ≥3.",9,16,0.5625,15,22,0.681818181818182,6,9,0.3,0.4091,0.375,0.4091,NA,NA,NA,5,"n","NA","USA","missing",NA,9.03,9.18,NA,62.5,59,"mdd",NA,-2.16216216216216,-1.44736842105263
"62",62,"Von Knorring","2006.0",0,"Citalopram","Placebo",NA,NA,"K-SADS-L",6,"clinician",32,5,124,32,5,120,NA,NA,79,NA,NA,74,NA,NA,NA,NA,NA,NA,"K-SADS depression and anhedonia scores ≤2",NA,NA,0.6,NA,NA,0.61,NA,NA,NA,NA,NA,NA,NA,NA,NA,12,"n","NA","European, multi-centered (31 recruitment sites)","13 to 18",NA,16,16,NA,NA,NA,"mdd",NA,NA,NA
"63",63,"Von Knorring","2006.0",0,"Citalopram","Placebo",NA,NA,"MADRS",3,"clinician",30,5.5,124,30,5.5,120,NA,NA,79,NA,NA,74,NA,NA,NA,NA,NA,NA,"50% improvement from baseline",NA,NA,0.61,NA,NA,0.59,NA,NA,NA,NA,NA,NA,NA,NA,NA,12,"n","NA","European, multi-centered (31 recruitment sites)","13 to 18",NA,16,16,NA,NA,NA,"mdd","*Ask Charlotte to check paper",NA,NA
"64",64,"Wagner","2003.0",0,"Sertraline","Placebo",NA,NA,"CDRS",1,"clinician",64.3,11,189,64.6,11,187,NA,NA,185,NA,NA,179,-22.84,NA,NA,-20.19,NA,NA,"40% improvement",128,185,0.691891891891892,106,179,0.592178770949721,NA,NA,NA,NA,NA,NA,NA,NA,NA,10,"y","Most common were oppositional defiant disorder, anxiety, adjustment reaction and phobic disorders.","International (USA, India, Canada, Costa Rica, Mexico)","6 to 17",NA,NA,NA,NA,57.1,44.9,"mdd",NA,NA,NA
"65",65,"Wagner","2003.0",0,"Sertraline","Placebo",NA,NA,"CGI-I",99,"clinician",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CGI scale improvement rating of 1 or 2",117,185,0.632432432432432,95,179,0.53072625698324,NA,NA,NA,NA,NA,NA,NA,NA,NA,10,"y","Most common were oppositional defiant disorder, anxiety, adjustment reaction and phobic disorders.","International (USA, India, Canada, Costa Rica, Mexico)","7 to 17",NA,NA,NA,NA,57.1,44.9,"mdd",NA,NA,NA
"66",66,"Wagner","2004.0",0,"Citalopram","Placebo",NA,NA,"CDRS",1,"clinician",58.8,10.9,89,57.8,11.1,85,NA,NA,89,NA,NA,85,NA,NA,NA,NA,NA,NA,"CDRS score ≤28",32,89,0.359550561797753,20,85,0.235294117647059,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,"y","Dysthmia, enuresis","USA","7 to 17",NA,12.1,12.1,NA,52.8,54.1,"mdd",NA,NA,NA
"67",67,"Wagner","2004.0",0,"Citalopram","Placebo",NA,NA,"CGI-I",99,"clinician",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CGI scale improvement rating of 1 or 2",42,89,0.471910112359551,38,85,0.447058823529412,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,"y","Dysthmia, enuresis","USA","7 to 17",NA,12.1,12.1,NA,52.8,54.1,"mdd",NA,NA,NA
"68",68,"Wagner","2006.0",0,"Escitalopram","Placebo",NA,NA,"CDRS",1,"clinician",54.5,NA,131,56.6,NA,133,NA,NA,NA,NA,NA,NA,-21.9,NA,129,-20.2,NA,132,"CDRS score ≤28",59,129,0.457364341085271,50,132,0.378787878787879,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,"y","Anxiety disorders (e.g. GAD, panic disorder, social phobia, specific phobia)","USA","6 to 17",NA,12.3,12.3,NA,51.9,51.9,"mdd",NA,NA,NA
"69",69,"Wagner","2006.0",0,"Escitalopram","Placebo",NA,NA,"CGI-I",99,"clinician",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"CGI scale improvement rating of 1 or 2",81,129,0.627906976744186,69,132,0.522727272727273,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,"y","Anxiety disorders (e.g. GAD, panic disorder, social phobia, specific phobia)","USA","6 to 17",NA,12.3,12.3,NA,51.9,51.9,"mdd",NA,NA,NA
"70",1,"Ackerson, 1998","1998",1,"cbt","wl","cbt","wlc","ham-d",2,"clinician",19.9,5.5,12,21,5,10,8.8,5.3,12,20.5,3.4,10,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,7,0,0.5833,0,0.5833,0,1,NA,NA,NA,NA,NA,NA,NA,16,NA,NA,64,NA,NA,NA,NA,-2.05555555555555,-0.119047619047619
"71",2,"Ackerson, 1998","1998",1,"cbt","wl","cbt","wlc","cdi",5,"self-report",19.2,7.1,12,16.8,4.5,10,9.4,6.7,12,15.8,5.2,10,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,7,0,0.5833,0,0.5833,0,2,NA,NA,NA,NA,NA,NA,NA,16,NA,NA,64,NA,NA,NA,NA,-1.42028985507246,-0.206185567010309
"72",3,"Ackerson, 1998","1998",1,"cbt","wl","cbt","wlc","cbcl-d",13,"parent_report",71.9,9.5,12,70.9,9.1,10,64.8,10.1,12,69.5,11.1,10,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,3,7,0.2,NA,NA,NA,NA,NA,16,NA,NA,64,NA,NA,NA,NA,-0.724489795918368,-0.138613861386139
"73",4,"Arnarson, 2009","2009",1,"cbt","cau","cbt","cau","DSM",99,"clinician",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,NA,NA,NA,NA,NA,NA,NA,14.5,NA,NA,51,NA,NA,NA,NA,NA,NA
"74",5,"Asarnow, 2002","2002",1,"cbt","wl","cbt + family education","wlc","cdi",5,"self-report",NA,NA,NA,NA,NA,NA,9.54,7.1,12,12.33,10.56,11,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,65,NA,NA,NA,NA,NA,NA
"75",6,"Bolton, 2007","2007",1,"ipt","wl","ipt","wlc","Acholi Psychosocial Assessment Instrument (APAI): a local instrument",99,"clinician",43.5,10.1,105,44.2,10.8,104,27.8,17.2,105,37.3,15.9,104,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,33,22,0.3143,0.2115,0.3143,0.2115,6,NA,NA,NA,NA,NA,NA,NA,14.97,NA,NA,57,NA,NA,NA,NA,-1.15018315018315,-0.51685393258427
"76",7,"Bolton, 2007","2007",1,"ipt","other ctr","ipt","creative play","Acholi Psychosocial Assessment Instrument (APAI): a local instrument",99,"clinician",43.5,10.1,105,44.2,11.2,105,27.8,17.2,105,40.6,15.7,105,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,32,21,0.3048,0.2,0.3048,0.2,7,39,14,NA,NA,NA,NA,NA,14.97,NA,NA,57,NA,NA,NA,NA,-1.15018315018315,-0.267657992565056
"77",8,"Charkhandeh, 2016","2016",1,"cbt","wl","cbt","wlc","cdi",5,"self-report",29.46,5.47,65,30.35,5.45,60,19.94,5.59,65,30.38,4.66,60,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,16,0,0.2462,0,0.2462,0,8,11,0.2,NA,NA,NA,NA,NA,15.26,NA,NA,54,NA,NA,NA,NA,-1.72151898734177,0.00593471810088973
"78",9,"Charkhandeh, 2016","2016",1,"cbt","other ctr","cbt","Reiki","cdi",5,"self-report",29.46,5.47,65,30,5.37,63,19.94,5.59,65,26.33,5.88,63,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,2,0.2,0.0317,0.2,0.0317,9,NA,NA,NA,NA,NA,NA,NA,15.26,NA,NA,54,NA,NA,NA,NA,-1.72151898734177,-0.652444444444445
"79",10,"Clarke, 1995","1995",1,"cbt","cau","cbt+cau","cau","ces-d",11,"self-report",24.29,9.6,55,21.88,9.2,70,17.88,9.3,52,21.67,12.3,68,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,10,0.2364,0.1429,0.25,0.1471,10,NA,NA,NA,NA,NA,NA,NA,15.3,NA,NA,7,NA,NA,NA,NA,-0.678306878306878,-0.01953488372093
"80",11,"Clarke, 1995","1995",1,"cbt","cau","cbt+cau","cau","ham-d",2,"clinician",3.55,3.2,55,3.86,3.1,70,1.87,2.5,52,2.91,4.3,68,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,25,0.3636,0.3571,0.3846,0.3676,11,25,28,NA,NA,NA,NA,NA,15.3,NA,NA,7,NA,NA,NA,NA,-0.589473684210526,-0.256756756756757
"81",12,"Clarke, 1999","1999",1,"cbt","wl","cbt","wlc","ham-d",2,"clinician",13,5.3,37,14.5,5.9,27,4.6,4.8,37,7.7,7,27,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,24,14,0.6486,0.5185,0.6486,0.5185,12,NA,NA,NA,NA,NA,NA,NA,16.2,NA,NA,71,NA,NA,NA,NA,-1.66336633663366,-1.05426356589147
"82",13,"Clarke, 1999","1999",1,"cbt","wl","cbt","wlc","bdi",4,"self-report",26.5,9.4,37,24.2,10.8,27,10.1,9.1,37,16,11.2,27,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,22,12,0.5946,0.4444,0.5946,0.4444,13,NA,NA,NA,NA,NA,NA,NA,16.2,NA,NA,71,NA,NA,NA,NA,-1.77297297297297,-0.745454545454545
"83",14,"Clarke, 1999","1999",1,"cbt","wl","cbt","wlc","cbcl-d",13,"parent_report",14.5,4,37,14.9,4.9,27,11.5,4.7,37,9,5.9,27,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,7,11,0.1892,0.4074,0.1892,0.4074,14,NA,NA,NA,NA,NA,NA,NA,16.2,NA,NA,71,NA,NA,NA,NA,-0.689655172413793,-1.09259259259259
"84",15,"Clarke, 1999","1999",1,"cbt","wl","cbt + parenting group","wlc","ham-d",2,"clinician",15.1,6,32,14.5,5.9,27,6.7,7.1,32,7.7,7,27,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,16,18,0.5,0.6667,0.5,0.6667,15,NA,NA,NA,NA,NA,NA,NA,16.2,NA,NA,71,NA,NA,NA,NA,-1.2824427480916,-1.05426356589147
"85",16,"Clarke, 1999","1999",1,"cbt","wl","cbt + parenting group","wlc","bdi",4,"self-report",26.4,8.7,32,24.2,10.8,27,13.3,10.9,32,16,11.2,27,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,11,0.625,0.4074,0.625,0.4074,16,24,7,NA,NA,NA,NA,NA,16.2,NA,NA,71,NA,NA,NA,NA,-1.33673469387755,-0.745454545454545
"86",17,"Clarke, 1999","1999",1,"cbt","wl","cbt + parenting group","wlc","cbcl-d",13,"parent_report",16.1,5.5,32,14.9,4.9,27,11.7,6.7,32,9,5.9,27,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,9,9,0.2812,0.3333,0.2812,0.3333,17,18,7,NA,NA,NA,NA,NA,16.2,NA,NA,71,NA,NA,NA,NA,-0.721311475409836,-1.09259259259259
"87",18,"Clarke, 2001","2001",1,"cbt","cau","cbt + cau","cau","ces-d",11,"self-report",25.2,8.7,45,23.8,10.3,49,17.8,8.7,45,22.5,11.3,49,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,9,0.2889,0.1837,0.2889,0.1837,18,NA,NA,NA,NA,NA,NA,NA,14.6,NA,NA,64,NA,NA,NA,NA,-0.850574712643678,-0.12037037037037
"88",19,"Clarke, 2001","2001",1,"cbt","cau","cbt + cau","cau","ham-d",2,"clinician",3.2,3.4,45,3.1,3.2,49,1.8,2.1,45,2.9,4.6,49,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,22,15,0.4889,0.3061,0.4889,0.3061,19,NA,NA,NA,NA,NA,NA,NA,14.6,NA,NA,64,NA,NA,NA,NA,-0.509090909090909,-0.0512820512820513
"89",20,"Clarke, 2001","2001",1,"cbt","cau","cbt + cau","cau","cbcl-d",13,"parent_report",8.8,5.3,45,6.8,4.1,49,7.8,5.5,45,6.4,3.5,49,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,11,13,0.2444,0.2653,0.2444,0.2653,20,18,18,NA,NA,NA,NA,NA,14.6,NA,NA,64,NA,NA,NA,NA,-0.185185185185185,-0.105263157894737
"90",21,"Clarke, 2002","2002",1,"cbt","cau","cbt + cau","cau","ces-d",11,"self-report",33.5,8.3,41,34.2,9.8,47,26.7,12.6,41,29.3,12.8,47,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,5,7,0.122,0.1489,0.122,0.1489,21,NA,NA,NA,NA,NA,NA,NA,15.3,NA,NA,69,NA,NA,NA,NA,-0.650717703349282,-0.433628318584071
"91",22,"Clarke, 2002","2002",1,"cbt","cau","cbt + cau","cau","ham-d",2,"clinician",12,5.3,41,11.4,5,47,5.5,5.2,41,6,5.1,47,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,23,22,0.561,0.4681,0.561,0.4681,22,NA,NA,NA,NA,NA,NA,NA,15.3,NA,NA,69,NA,NA,NA,NA,-1.23809523809524,-1.06930693069307
"92",23,"Clarke, 2002","2002",1,"cbt","cau","cbt + cau","cau","cbcl-d",13,"parent_report",9.6,5.3,41,9.3,5.7,47,10.2,5.8,41,8.9,5.1,47,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,5,13,0.122,0.2766,0.122,0.2766,23,22,22,NA,NA,NA,NA,NA,15.3,NA,NA,69,NA,NA,NA,NA,0.108108108108108,-0.0740740740740741
"93",24,"Curry, 2021","2021",1,"cbt","cau","cbt-d (CBT targeting depression)","ETAU","cdrs-r",1,"clinician",49.84,7.66,25,45.04,6.07,25,41.1,11.14,25,35.87,9.32,25,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,3,0.12,0.12,0.12,0.12,24,NA,NA,NA,NA,NA,NA,NA,17.3,NA,NA,33,NA,NA,NA,NA,-0.929787234042553,-1.19168291098116
"94",25,"De Cuyper, 2004","2004",1,"cbt","wl","cbt","wlc","cdi",5,"self-report",12.67,6,9,15.27,4.54,11,10.11,6.03,9,11.73,5.66,11,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,3,0.4444,0.2727,0.4444,0.2727,25,2,3,NA,NA,NA,NA,NA,10,NA,NA,75,NA,NA,NA,NA,-0.425602660016625,-0.694117647058823
"95",26,"De Jonge-Heesen, 2020","2020",1,"cbt","other ctr","cbt","psychoeducation","cdi",5,"self-report",16.18,4.92,66,15.68,7.08,64,13.32,7.07,66,14.71,9.06,64,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,14,15,0.2121,0.2344,0.2121,0.2344,26,15,14,NA,NA,NA,NA,NA,13.59,NA,NA,64,NA,NA,NA,NA,-0.477064220183486,-0.120198265179678
"96",27,"De Jonge-Heesen, 2020","2020",1,"cbt","other ctr","cbt","psychoeducation","cdi",5,"parent_report",20.14,5.54,66,5.86,2.57,64,18.66,6,66,15.09,6.36,64,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,6,1,0.0909,0.0156,0.0909,0.0156,27,NA,NA,NA,NA,NA,NA,NA,13.59,NA,NA,64,NA,NA,NA,NA,-0.256499133448874,2.06718924972005
"97",28,"Diamond, 2002","2002",1,"other psy","wl","abft (attachment based family therapy)","wlc","bdi",4,"self-report",23.8,7.4,16,28,7.1,16,11.8,8.8,16,18.5,11.1,16,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,5,7,0.3125,0.4375,0.3125,0.4375,28,9,5,NA,NA,NA,NA,NA,14.9,NA,NA,78,NA,NA,NA,NA,-1.48148148148148,-1.04395604395604
"98",29,"Do, 2021","2021",1,"cbt","wl","ccbt","wlc","phq-9",99,"self-report",9.24,4.62,25,11.92,6.87,25,5.84,3.74,25,10.44,6.28,25,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,9,0.32,0.36,0.32,0.36,29,NA,NA,NA,NA,NA,NA,NA,15.7,NA,NA,54,NA,NA,NA,NA,-0.813397129186603,-0.225095057034221
"99",30,"Do, 2021","2021",1,"cbt","wl","ccbt","wlc","ces-d",11,"self-report",23.12,9.36,25,25.36,15.4,25,13.4,8.43,25,22.48,14.21,25,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,4,0.32,0.16,0.32,0.16,30,NA,NA,NA,NA,NA,NA,NA,15.7,NA,NA,54,NA,NA,NA,NA,-1.09274873524452,-0.194528875379939
"100",31,"Esposito-Smythers, 2019","2019",1,"cbt","cau","cbt","cau","cdi",5,"self-report",27,8.7,74,26.3,9.8,73,13.2,9.3,64,13.8,9.2,62,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,31,33,0.4189,0.4521,0.4844,0.5323,31,NA,NA,NA,NA,NA,NA,NA,14.9,NA,NA,76,NA,NA,NA,NA,-1.53333333333333,-1.31578947368421
"101",32,"Fristad, 2019","2019",1,"cbt","other ctr","cbt + placebo","placebo","cdrs-r",1,"clinician",42,9,19,44,13,18,30,9,18,31,11,18,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,3,0.1053,0.1667,0.1111,0.1667,32,25,21,NA,NA,NA,NA,NA,16,NA,NA,431,NA,NA,NA,NA,-1.33333333333333,-1.08333333333333
"102",33,"Gillham, 2006","2006",1,"cbt","cau","cbt","cau","cdi",5,"self-report",13.19,7.81,147,12.57,7.17,124,11.55,8.21,112,11.37,7.9,104,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,29,23,0.1973,0.1855,0.2589,0.2212,33,NA,NA,NA,NA,NA,NA,NA,11.5,NA,NA,53,NA,NA,NA,NA,-0.204744069912609,-0.159256801592568
"103",34,"Idsoe, 2019","2019",1,"cbt","cau","cbt","cau","ces-d",11,"self-report",33.08,9.97,133,32.01,9.75,95,26.85,11.82,133,29.55,10.77,95,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,26,13,0.1955,0.1368,0.1955,0.1368,34,31,27,NA,NA,NA,NA,NA,16.7,NA,NA,88,NA,NA,NA,NA,-0.571821936668196,-0.239766081871345
"104",35,"Israel, 2013","2013",1,"other psy","cau","abft (attachment based family therapy)","cau","ham-d",2,"clinician",20.6,4.6,11,19.7,5.5,9,12.5,7.2,11,19.4,5.2,9,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,1,0.3636,0.1111,0.3636,0.1111,35,25,10,NA,NA,NA,NA,NA,15.6,NA,NA,55,NA,NA,NA,NA,-1.3728813559322,-0.0560747663551403
"105",36,"Israel, 2013","2013",1,"other psy","cau","abft (attachment based family therapy)","cau","bdi",4,"self-report",31.9,9.1,11,29.7,11.2,9,22.8,12,11,31.2,8.8,9,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,0,0.2727,0,0.2727,0,36,NA,NA,NA,NA,NA,NA,NA,15.6,NA,NA,55,NA,NA,NA,NA,-0.862559241706161,0.15
"106",37,"Kahn, 1990","1990",1,"cbt","wl","cbt","wlc","cdi",5,"self-report",31.11,9.58,17,28.06,9.75,17,7.29,66.03,17,26.94,15.41,17,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,11,1,0.6471,0.0588,0.6471,0.0588,37,4,0.2,NA,NA,NA,NA,NA,12.1,NA,NA,52,NA,NA,NA,NA,-0.630075386853591,-0.0890302066772653
"107",38,"Kahn, 1990","1990",1,"cbt","wl","cbt","wlc","rads",8,"self-report",87,8.96,17,85.41,10.98,17,53.44,14.72,17,80.12,13.44,17,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,5,0,0.2941,0,0.2941,0,38,NA,NA,NA,NA,NA,NA,NA,12.1,NA,NA,52,NA,NA,NA,NA,-2.83445945945946,-0.433251433251433
"108",39,"Kahn, 1990","1990",1,"cbt","wl","cbt","wlc","bid",9,"self-report",44.65,15.56,17,42.82,13.6,17,15.65,10.03,17,29.7,16.66,17,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,5,0.7647,0.2941,0.7647,0.2941,39,NA,NA,NA,NA,NA,NA,NA,12.1,NA,NA,52,NA,NA,NA,NA,-2.26651035560766,-0.867151354923992
"109",40,"Kahn, 1990","1990",1,"other psy","wl","self-modeling","wlc","cdi",5,"self-report",27.18,7.84,17,28.06,9.75,17,13.58,7.38,17,26.94,15.41,17,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,6,7,0.3529,0.4118,0.3529,0.4118,40,NA,NA,NA,NA,NA,NA,NA,12.1,NA,NA,52,NA,NA,NA,NA,-1.78712220762155,-0.0890302066772653
"110",41,"Kahn, 1990","1990",1,"other psy","wl","self-modeling","wlc","rads",8,"self-report",81.65,10.66,17,85.41,10.98,17,62.12,12,17,80.12,13.44,17,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,0,0.0588,0,0.0588,0,41,11,3,NA,NA,NA,NA,NA,12.1,NA,NA,52,NA,NA,NA,NA,-1.72374227714034,-0.433251433251433
"111",42,"Kahn, 1990","1990",1,"other psy","wl","self-modeling","wlc","bid",9,"self-report",52.82,18.45,17,42.82,13.6,17,17.59,14.73,17,29.7,16.66,17,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,10,0.7647,0.5882,0.7647,0.5882,42,8,3,NA,NA,NA,NA,NA,12.1,NA,NA,52,NA,NA,NA,NA,-2.12356841470766,-0.867151354923992
"112",43,"Kahn, 1990","1990",1,"cbt","other ctr","cbt","Relaxation","cdi",5,"self-report",31.11,9.58,17,26.94,10.83,17,7.29,66.03,17,12.88,10.71,17,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,10,7,0.5882,0.4118,0.5882,0.4118,43,NA,NA,NA,NA,NA,NA,NA,12.1,NA,NA,52,NA,NA,NA,NA,-0.630075386853591,-1.30547818012999
"113",44,"Kahn, 1990","1990",1,"cbt","other ctr","cbt","Relaxation","rads",8,"self-report",87,8.96,17,83.44,8.03,17,53.44,14.72,17,61.76,14.86,17,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,6,2,0.3529,0.1176,0.3529,0.1176,44,NA,NA,NA,NA,NA,NA,NA,12.1,NA,NA,52,NA,NA,NA,NA,-2.83445945945946,-1.89427697684578
"114",45,"Kahn, 1990","1990",1,"cbt","other ctr","cbt","Relaxation","bid",9,"self-report",44.65,15.56,17,38.06,15.26,17,15.65,10.03,17,19.18,20.42,17,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,12,10,0.7059,0.5882,0.7059,0.5882,45,NA,NA,NA,NA,NA,NA,NA,12.1,NA,NA,52,NA,NA,NA,NA,-2.26651035560766,-1.05829596412556
"115",46,"Kitchen, 2021","2021",1,"bat","cau","bat","cau","mfq",7,"self-report",33.91,11.8,11,35.55,11.09,11,23.43,9.59,7,30.5,8.67,8,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,4,0.0909,0.3636,0.1429,0.5,46,NA,NA,NA,NA,NA,NA,NA,15.66,NA,NA,82,NA,NA,NA,NA,-0.979897148200093,-0.511133603238866
"116",47,"Kitchen, 2021","2021",1,"bat","cau","bat","cau","mfq",7,"parent_report",29.83,7.36,11,29,8.58,11,29.33,8.62,7,26.6,15.79,8,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,1,0,0.0909,0,0.125,47,2,1,NA,NA,NA,NA,NA,15.66,NA,NA,82,NA,NA,NA,NA,-0.0625782227784731,-0.196963479688141
"117",48,"Lewinsohn, 1990","1990",1,"cbt","wl","cwb adolescents only","wlc","ces-d",11,"self-report",13.29,5.21,21,14.89,4.3,19,7.19,4.88,21,12.89,4.74,19,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,12,2,0.5714,0.1053,0.5714,0.1053,48,NA,NA,NA,NA,NA,NA,NA,16.2,NA,NA,61,NA,NA,NA,NA,-1.20911793855302,-0.442477876106195
"118",49,"Lewinsohn, 1990","1990",1,"cbt","wl","cwb adolescents only","wlc","bdi",4,"self-report",21.67,11.34,21,23.84,11.43,19,10,11.91,21,20.47,10.28,19,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,9,2,0.4286,0.1053,0.4286,0.1053,49,11,4,NA,NA,NA,NA,NA,16.2,NA,NA,61,NA,NA,NA,NA,-1.00387096774194,-0.310456011054814
"119",50,"Lewinsohn, 1990","1990",1,"cbt","wl","cwb adolescents only","wlc","cbcl-d",13,"parent_report",13.67,4.03,21,12.84,5.5,19,8.95,5.42,21,8.31,4.2,19,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,8,0.1905,0.4211,0.1905,0.4211,50,13,4,NA,NA,NA,NA,NA,16.2,NA,NA,61,NA,NA,NA,NA,-0.998941798941799,-0.934020618556701
"120",51,"Lewinsohn, 1990","1990",1,"cbt","wl","cwb adolescents + parents","wlc","ces-d",11,"self-report",12.84,6.65,19,14.89,4.3,19,5.68,4.78,19,12.89,4.74,19,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,11,4,0.5789,0.2105,0.5789,0.2105,51,NA,NA,NA,NA,NA,NA,NA,16.2,NA,NA,65,NA,NA,NA,NA,-1.25284339457568,-0.442477876106195
"121",52,"Lewinsohn, 1990","1990",1,"cbt","wl","cwb adolescents + parents","wlc","bdi",4,"self-report",21.26,11.35,19,23.84,11.43,19,6.47,8.53,19,20.47,10.28,19,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,12,3,0.6316,0.1579,0.6316,0.1579,52,NA,NA,NA,NA,NA,NA,NA,16.2,NA,NA,65,NA,NA,NA,NA,-1.48792756539235,-0.310456011054814
"122",53,"Lewinsohn, 1990","1990",1,"cbt","wl","cwb adolescents + parents","wlc","cbcl-d",13,"parent_report",13.05,4.93,19,12.84,5.5,19,3.52,2.73,19,8.31,4.2,19,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,19,0,1,0,1,0,53,NA,NA,NA,NA,NA,NA,NA,16.2,NA,NA,65,NA,NA,NA,NA,-2.48825065274151,-0.934020618556701
"123",54,"Liddle, 1990","1990",1,"cbt","wl","cbt","wlc","cdi",5,"self-report",21,4.45,11,20.7,3.34,10,14.45,6.74,11,16.9,6.79,10,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,1,0.1818,0.1,0.1818,0.1,54,NA,NA,NA,NA,NA,NA,NA,9.2,NA,NA,32,NA,NA,NA,NA,-1.17068811438785,-0.750246791707799
"124",55,"Liddle, 1990","1990",1,"cbt","other ctr","cbt (social competence training)","attention placebo (drama)","cdi",5,"self-report",21,4.45,11,22.3,4.24,10,14.45,6.74,11,19.3,6.93,10,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,1,0.2727,0.1,0.2727,0.1,55,3,2,NA,NA,NA,NA,NA,9.2,NA,NA,32,NA,NA,NA,NA,-1.17068811438785,-0.53715308863026
"125",56,"Listug-Lunde, 2013","2013",1,"cbt","cau","cwd","cau","cdi",5,"self-report",21,5.29,8,20.37,4.1,8,14.38,9.93,8,13.25,9.87,8,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,3,0.375,0.375,0.375,0.375,56,NA,NA,NA,NA,NA,NA,NA,12.44,NA,NA,38,NA,NA,NA,NA,-0.869908015768725,-1.01932712956335
"126",57,"Luby, 2012","2012",1,"other psy","other ctr","PCIT-ED intervention (Parent-Child Interaction Therapy Emotion Development)","psychoeducation","PFCâ€“S",99,"parent_report",42.8,5.8,25,39.8,10.3,18,30.1,11.3,25,33.7,10.6,18,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,7,2,0.28,0.1111,0.28,0.1111,57,3,3,NA,NA,NA,NA,NA,4.349,NA,NA,37,NA,NA,NA,NA,-1.48538011695906,-0.583732057416267
"127",58,"Luby, 2012","2012",1,"other psy","other ctr","PCIT-ED intervention (Parent-Child Interaction Therapy Emotion Development)","psychoeducation","PAPA",99,"parent_report",11.3,4.2,25,9,4.7,18,7.6,4,25,7.5,4.7,18,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,4,0.32,0.2222,0.32,0.2222,58,10,5,NA,NA,NA,NA,NA,4.349,NA,NA,37,NA,NA,NA,NA,-0.902439024390244,-0.319148936170213
"128",59,"Makover, 2019","2019",1,"other psy","cau","The High School Transition Program (HSTP)","cau","smfq",7,"self-report",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,59,NA,NA,NA,NA,NA,NA,NA,13.5,NA,NA,61,NA,NA,NA,NA,NA,NA
"129",60,"March, 2004","2004",1,"cbt","other ctr","cbt","placebo","cdrs-r",1,"clinician",59.64,4.52,111,61.18,4.27,112,42.06,9.18,111,41.77,7.99,112,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,12,9,0.1081,0.0804,0.1081,0.0804,60,NA,NA,NA,NA,NA,NA,NA,14.6,NA,NA,54,NA,NA,NA,NA,-2.56642335766423,-3.16639477977161
"130",61,"March, 2004","2004",1,"cbt","other ctr","cbt","placebo","rads",8,"self-report",78.69,10.59,111,81.26,9.22,112,67.96,14.18,111,66.68,11.41,112,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,5,0,0.045,0,0.045,0,61,10,9,NA,NA,NA,NA,NA,14.6,NA,NA,54,NA,NA,NA,NA,-0.866370609608398,-1.4134755210858
"131",62,"Martinovic, 2006","2006",1,"cbt","cau","cbt","cau","ham-d",2,"clinician",5.9,0.8,16,5.7,0.7,16,3.3,1.29,15,5.8,1.98,15,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,5,1,0.3125,0.0625,0.3333,0.0667,62,NA,NA,NA,NA,NA,NA,NA,17.4,NA,NA,68,NA,NA,NA,NA,-2.48803827751196,0.0746268656716415
"132",63,"Martinovic, 2006","2006",1,"cbt","cau","cbt","cau","bdi",4,"self-report",8.2,0.94,16,8.1,0.96,16,5.4,2.97,15,7.8,2.66,15,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,1,0.1875,0.0625,0.2,0.0667,63,NA,NA,NA,NA,NA,NA,NA,17.4,NA,NA,68,NA,NA,NA,NA,-1.43222506393862,-0.165745856353591
"133",64,"Martinovic, 2006","2006",1,"cbt","cau","cbt","cau","ces-d",11,"self-report",14.1,4.52,16,13.9,4.51,16,9.8,4.2,15,13.6,4.64,15,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,5,2,0.3125,0.125,0.3333,0.1333,64,NA,NA,NA,NA,NA,NA,NA,17.4,NA,NA,68,NA,NA,NA,NA,-0.986238532110092,-0.0655737704918034
"134",65,"Moeini, 2019","2019",1,"cbt","cau","DAD (Dorehye Amozeshie Dokhtaran)",NA,"ces-d",11,"self-report",24.6,11.7,64,22.3,11.8,64,18.5,14,64,21.4,15.6,64,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,22,21,0.3438,0.3281,0.3438,0.3281,65,6,1,NA,NA,NA,NA,NA,16.7,NA,NA,1,NA,NA,NA,NA,-0.474708171206226,-0.0656934306569345
"135",66,"Mufson, 1999","1999",1,"ipt","other ctr","ipt","clinical monitoring","ham-d",2,"clinician",19.2,7.5,24,18.7,8.6,24,6.3,7.7,24,11.8,8.9,24,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,10,0.7083,0.4167,0.7083,0.4167,66,21,16,NA,NA,NA,NA,NA,15.8,NA,NA,73,NA,NA,NA,NA,-1.69736842105263,-0.788571428571428
"136",67,"Mufson, 1999","1999",1,"ipt","other ctr","ipt","clinical monitoring","bdi",4,"self-report",18.8,8.5,24,22.8,10.6,24,5.9,8.1,24,12.9,12.6,24,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,18,12,0.75,0.5,0.75,0.5,67,NA,NA,NA,NA,NA,NA,NA,15.8,NA,NA,73,NA,NA,NA,NA,-1.55421686746988,-0.853448275862069
"137",68,"Mufson, 2004","2004",1,"ipt","cau","ipt","cau","ham-d",2,"clinician",18.9,5.9,34,18.3,5,29,8.7,8,34,12.8,8.4,29,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,19,7,0.5588,0.2414,0.5588,0.2414,68,16,9,NA,NA,NA,NA,NA,15.1,NA,NA,84,NA,NA,NA,NA,-1.46762589928058,-0.82089552238806
"138",69,"Mufson, 2004","2004",1,"ipt","cau","ipt","cau","bdi",4,"self-report",20.8,8.7,34,21.8,8.5,29,8.4,11,34,12.3,9.7,29,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,23,9,0.6765,0.3103,0.6765,0.3103,69,NA,NA,NA,NA,NA,NA,NA,15.1,NA,NA,84,NA,NA,NA,NA,-1.25888324873096,-1.04395604395604
"139",70,"Reynolds, 1986","1986",1,"cbt","wl","cbt","wlc","bdi",4,"self-report",21.11,7.75,9,16.9,5.48,10,6.36,3.15,6,18.31,9.82,10,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,5,3,0.5556,0.3,0.8333,0.3,70,18,10,NA,NA,NA,NA,NA,15.7,NA,NA,63,NA,NA,NA,NA,-2.70642201834862,0.184313725490196
"140",71,"Reynolds, 1986","1986",1,"cbt","wl","cbt","wlc","bid",9,"self-report",50.33,19.6,9,36.9,12.17,10,16,17.83,6,52.36,14.73,10,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,5,0,0.5556,0,0.8333,0,71,NA,NA,NA,NA,NA,NA,NA,15.7,NA,NA,63,NA,NA,NA,NA,-1.83435746727224,1.14944237918216
"141",72,"Reynolds, 1986","1986",1,"cbt","wl","cbt","wlc","rads",8,"self-report",85.67,8.4,9,80.7,3.58,10,66.74,7.47,6,81.12,13.46,10,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,72,5,2,NA,NA,NA,NA,NA,15.7,NA,NA,63,NA,NA,NA,NA,-2.38563327032136,0.0492957746478875
"142",73,"Reynolds, 1986","1986",1,"cbt","other ctr","cbt","Relaxation training","bdi",4,"self-report",21.11,7.75,9,17.09,6.36,11,6.36,3.15,6,5.77,4,8,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,6,6,0.6667,0.5455,1,0.75,73,NA,NA,NA,NA,NA,NA,NA,15.7,NA,NA,63,NA,NA,NA,NA,-2.70642201834862,-2.18532818532819
"143",74,"Reynolds, 1986","1986",1,"cbt","other ctr","cbt","Relaxation training","bid",9,"self-report",50.33,19.6,9,46.27,20.42,11,16,17.83,6,19.45,11.97,8,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,5,8,0.5556,0.7273,0.8333,1,74,NA,NA,NA,NA,NA,NA,NA,15.7,NA,NA,63,NA,NA,NA,NA,-1.83435746727224,-1.65606668724915
"144",75,"Reynolds, 1986","1986",1,"cbt","other ctr","cbt","Relaxation training","rads",8,"self-report",85.67,8.4,9,80.09,6.99,11,66.74,7.47,6,65.8,9.52,8,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,75,NA,NA,NA,NA,NA,NA,NA,15.7,NA,NA,63,NA,NA,NA,NA,-2.38563327032136,-1.73107207752877
"145",76,"Rohde, 2004","2004",1,"cbt","other ctr","cbt","life skills/tutoring","bdi",4,"self-report",16.6,12.8,45,9.6,10.7,48,9.6,10.7,44,11.5,11.1,47,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,19,9,0.4222,0.1875,0.4318,0.1915,76,NA,NA,NA,NA,NA,NA,NA,15.1,NA,NA,48,NA,NA,NA,NA,-0.595744680851064,0.174311926605505
"146",77,"Rohde, 2004","2004",1,"cbt","other ctr","cbt","life skills/tutoring","ham-d",2,"clinician",14.2,5.2,45,6,6.3,48,6,6.3,44,8.3,5.4,47,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,24,4,0.5333,0.0833,0.5455,0.0851,77,NA,NA,NA,NA,NA,NA,NA,15.1,NA,NA,48,NA,NA,NA,NA,-1.42608695652174,0.393162393162393
"147",78,"Rossello, 1999","1999",1,"cbt","wl","cbt","wlc","cdi",5,"self-report",20.12,6.95,25,20.13,5.99,23,13.28,7.61,21,15.83,6.83,18,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,7,4,0.28,0.1739,0.3333,0.2222,78,25,8,NA,NA,NA,NA,NA,14.7,NA,NA,54,NA,NA,NA,NA,-0.93956043956044,-0.670826833073323
"148",79,"Rossello, 1999","1999",1,"ipt","wl","ipt","wlc","cdi",5,"self-report",21.21,7.53,23,20.13,5.99,23,10.79,6.51,19,15.83,6.83,18,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,3,0.3478,0.1304,0.4211,0.1667,79,NA,NA,NA,NA,NA,NA,NA,14.7,NA,NA,54,NA,NA,NA,NA,-1.48433048433048,-0.670826833073323
"149",80,"Sanford, 2006","2006",1,"other psy","cau","Family Psychoeducation (FPE) + cau","cau","rads",8,"self-report",NA,NA,16,NA,NA,15,NA,NA,16,NA,NA,15,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,80,7,4,NA,NA,NA,NA,NA,15.9,NA,NA,65,NA,NA,NA,NA,NA,NA
"150",81,"Santomauro, 2016","2016",1,"cbt","wl","cbt","wlc","dass",99,"self-report",24.2,8.97,11,21.6,11.03,12,17.2,8.95,10,23.93,11.58,10,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,2,0.1818,0.1667,0.2,0.2,81,9,4,NA,NA,NA,NA,NA,15.7,NA,NA,4,NA,NA,NA,NA,-0.78125,0.20610349402919
"151",82,"Schniering, 2022","2022",1,"cbt","wl","The Internet based Chilled Plus Program (CP)","wl","smfq",7,"self-report",14.4,6.1,45,14.57,6.08,46,8.59,11.2,45,14.51,10.44,46,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,10,0.4444,0.2174,0.4444,0.2174,82,NA,NA,NA,NA,NA,NA,NA,14.29,NA,NA,66,NA,NA,NA,NA,-0.671676300578035,-0.00726392251815987
"152",83,"Schniering, 2022","2022",1,"cbt","wl","The Internet based Chilled Plus Program (CP)","wl","smfq",7,"parent_report",12.82,4.93,45,12.1,4.99,46,6.92,6.47,45,9.1,7.12,46,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,15,14,0.3333,0.3043,0.3333,0.3043,83,3,1,NA,NA,NA,NA,NA,14.29,NA,NA,66,NA,NA,NA,NA,-1.03508771929825,-0.495458298926507
"153",84,"Shomaker, 2016","2016",1,"cbt","other ctr","cbt","psychoeducation","ces-d",11,"self-report",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,84,NA,NA,NA,NA,NA,NA,NA,15,NA,NA,1,NA,NA,NA,NA,NA,NA
"154",85,"Srivastava, 2020","2020",1,"cbt","cau","cCBT","cau","bdi",4,"self-report",26.4,3.4,11,24.3,3.8,10,10.5,1.4,10,15.7,5.9,9,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,9,2,0.8182,0.2,0.9,0.2222,85,NA,NA,NA,NA,NA,NA,NA,16.05,NA,NA,24,NA,NA,NA,NA,-6.625,-1.77319587628866
"155",86,"Srivastava, 2020","2020",1,"cbt","cau","cCBT","cau","cdrs-r",1,"self-report",67.8,3.1,11,66.9,3.4,10,33.7,11.2,10,45.3,9.7,9,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,0,0.2727,0,0.3,0,86,NA,NA,NA,NA,NA,NA,NA,16.05,NA,NA,24,NA,NA,NA,NA,-4.76923076923077,-3.29770992366412
"156",87,"Stallard, 2012","2012",1,"cbt","other ctr","cbt","attention control","smfq",7,"self-report",10.64,4.91,392,10.6,4.67,374,8.22,6.45,296,8.5,5.88,308,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,89,82,0.227,0.2193,0.3007,0.2662,87,NA,NA,NA,NA,NA,NA,NA,14.3,NA,NA,65,NA,NA,NA,NA,-0.426056338028169,-0.398104265402843
"157",88,"Stallard, 2012","2012",1,"cbt","cau","cbt","cau","smfq",7,"self-report",10.64,4.91,392,10.56,4.93,298,8.22,6.45,296,6.81,5.7,242,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,102,95,0.2602,0.3188,0.3446,0.3926,88,NA,NA,NA,NA,NA,NA,NA,14.3,NA,NA,65,NA,NA,NA,NA,-0.426056338028169,-0.705550329256821
"158",89,"Stark, 1987","1987",1,"pst","wl","pst","wlc","cdi",5,"self-report",22.4,8.47,10,20.11,9.88,9,9.04,8.32,10,18.6,9.91,9,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,6,1,0.6,0.1111,0.6,0.1111,89,NA,NA,NA,NA,NA,NA,NA,11.17,NA,NA,43,NA,NA,NA,NA,-1.59142346634902,-0.152602324406266
"159",90,"Stark, 1987","1987",1,"pst","wl","pst","wlc","CDS",10,"self-report",71.1,10.38,10,67.56,17.8,9,55.1,12.18,10,61.09,16.73,9,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,1,0.1,0.1111,0.1,0.1111,90,97,90,NA,NA,NA,NA,NA,11.17,NA,NA,43,NA,NA,NA,NA,-1.41843971631206,-0.374746597161888
"160",91,"Stark, 1987","1987",1,"pst","wl","pst","wlc","cdrs-r",1,"clinician",33.5,10.27,10,30.33,6.28,9,24.16,6.01,10,28.15,6.21,9,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,91,NA,NA,NA,NA,NA,NA,NA,11.17,NA,NA,43,NA,NA,NA,NA,-1.14742014742015,-0.349079263410729
"161",92,"Stark, 1987","1987",1,"pst","wl","pst","wlc","cbcl-d",13,"parent_report",72.33,9.98,10,64,11.28,9,63.41,10.01,10,67.62,11.15,9,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,92,NA,NA,NA,NA,NA,NA,NA,11.17,NA,NA,43,NA,NA,NA,NA,-0.892446223111556,0.322781988408382
"162",93,"Stark, 1987","1987",1,"other psy","wl","self control","wlc","cdi",5,"self-report",21.6,5.48,9,20.11,9.88,9,8.04,6.65,9,18.6,9.91,9,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,5,1,0.5556,0.1111,0.5556,0.1111,93,NA,NA,NA,NA,NA,NA,NA,11.17,NA,NA,43,NA,NA,NA,NA,-2.23577906018137,-0.152602324406266
"163",94,"Stark, 1987","1987",1,"other psy","wl","self control","wlc","CDS",10,"self-report",72.4,10.31,9,67.56,17.8,9,50.14,8.68,9,61.09,16.73,9,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,94,NA,NA,NA,NA,NA,NA,NA,11.17,NA,NA,43,NA,NA,NA,NA,-2.34439178515008,-0.374746597161888
"164",95,"Stark, 1987","1987",1,"other psy","wl","self control","wlc","cdrs-r",1,"clinician",37.22,8.36,9,30.33,6.28,9,22.91,4.36,9,28.15,6.21,9,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,95,1,0.2,NA,NA,NA,NA,NA,11.17,NA,NA,43,NA,NA,NA,NA,-2.25,-0.349079263410729
"165",96,"Stark, 1987","1987",1,"other psy","wl","self control","wlc","cbcl-d",13,"parent_report",69.44,6.77,9,64,11.28,9,66.91,9.73,9,67.62,11.15,9,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,96,1,0.2,NA,NA,NA,NA,NA,11.17,NA,NA,43,NA,NA,NA,NA,-0.306666666666667,0.322781988408382
"166",97,"Stice, 2008","2008",1,"cbt","cau","cbt","assessment only","bdi",4,"self-report",20.03,10.35,89,19.6,9.23,84,10.77,9.04,89,16.71,9.74,84,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,22,0.4607,0.2619,0.4607,0.2619,97,NA,NA,NA,NA,NA,NA,NA,15.6,NA,NA,56,NA,NA,NA,NA,-0.95513151108819,-0.304691618344755
"167",98,"Stice, 2008","2008",1,"cbt","cau","cbt","assessment only","K-SADS",6,"clinician",1.87,0.35,89,1.8,0.3,84,1.53,0.33,89,1.7,0.36,84,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,1,0.0337,0.0119,0.0337,0.0119,98,NA,NA,NA,NA,NA,NA,NA,15.6,NA,NA,56,NA,NA,NA,NA,-1,-0.303030303030303
"168",99,"Stice, 2008","2008",1,"cbt","cau","cbt based bibliotherapy","assessment only","bdi",4,"self-report",18.2,7.53,80,19.6,9.23,84,14.25,8.98,80,16.71,9.74,84,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,19,21,0.2375,0.25,0.2375,0.25,99,NA,NA,NA,NA,NA,NA,NA,15.6,NA,NA,56,NA,NA,NA,NA,-0.478497880072683,-0.304691618344755
"169",100,"Stice, 2008","2008",1,"cbt","cau","cbt based bibliotherapy","assessment only","K-SADS",6,"clinician",1.68,0.31,80,1.8,0.3,84,1.6,0.35,80,1.7,0.36,84,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,2,0,0.0238,0,0.0238,100,30,20,NA,NA,NA,NA,NA,15.6,NA,NA,56,NA,NA,NA,NA,-0.242424242424242,-0.303030303030303
"170",101,"Stice, 2008","2008",1,"sup","cau","sup","assessment only","bdi",4,"self-report",20.27,9.83,88,19.6,9.23,84,14.67,10.62,88,16.71,9.74,84,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,27,27,0.3068,0.3214,0.3068,0.3214,101,42,20,NA,NA,NA,NA,NA,15.6,NA,NA,56,NA,NA,NA,NA,-0.547677261613692,-0.304691618344755
"171",102,"Stice, 2008","2008",1,"sup","cau","sup","assessment only","K-SADS",6,"clinician",1.84,0.37,88,1.8,0.3,84,1.62,0.33,88,1.7,0.36,84,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,2,0,0.0238,0,0.0238,102,NA,NA,NA,NA,NA,NA,NA,15.6,NA,NA,56,NA,NA,NA,NA,-0.628571428571429,-0.303030303030303
"172",103,"Stikkelbroek, 2020","2020",1,"cbt","cau","cbt","cau","K-SADS",6,"clinician",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,103,NA,NA,NA,NA,NA,NA,NA,16.6,NA,NA,82,NA,NA,NA,NA,NA,NA
"173",104,"Szigethy, 2007","2007",1,"cbt","cau","cbt","cau","cdi",5,"self-report",25.7,10.8,22,21.8,8.1,19,10.7,8,21,16.7,11.1,19,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,11,6,0.5,0.3158,0.5238,0.3158,104,NA,NA,NA,NA,NA,NA,NA,15,NA,NA,51,NA,NA,NA,NA,-1.59574468085106,-0.53125
"174",105,"Szigethy, 2007","2007",1,"cbt","cau","cbt","cau","K-SADS",6,"clinician",2.3,1.8,22,2.3,1.2,19,1,1.2,21,2.4,2.3,19,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,12,5,0.5455,0.2632,0.5714,0.2632,105,NA,NA,NA,NA,NA,NA,NA,15,NA,NA,51,NA,NA,NA,NA,-0.866666666666667,0.0571428571428572
"175",106,"Topooco, 2019","2019",1,"cbt","other ctr","icbt","minimal attention controlÂ ","bdi",4,"self-report",31.6,10,35,28.8,7.9,35,16,11.3,31,24.8,10.4,35,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,12,4,0.3429,0.1143,0.3871,0.1143,106,13,6,NA,NA,NA,NA,NA,17.5,NA,NA,96,NA,NA,NA,NA,-1.46478873239437,-0.437158469945355
"176",107,"Vostanis, 1996","1996",1,"cbt","other ctr","cbt","non-focused intervention","mfq",7,"self-report",33.4,12.2,29,28.6,14.4,28,17.6,5.2,29,18.4,15.8,28,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,15,12,0.5172,0.4286,0.5172,0.4286,107,NA,NA,NA,NA,NA,NA,NA,12.7,NA,NA,56,NA,NA,NA,NA,-1.81609195402299,-0.675496688741722
"177",108,"Vostanis, 1996","1996",1,"cbt","other ctr","cbt","non-focused intervention","mfq",7,"parent_report",30,12,29,32.5,15.1,28,13.4,9.2,29,19.4,13.7,28,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,15,11,0.5172,0.3929,0.5172,0.3929,108,NA,NA,NA,NA,NA,NA,NA,12.7,NA,NA,56,NA,NA,NA,NA,-1.56603773584906,-0.909722222222222
"178",109,"Weisz, 1997","1997",1,"cbt","cau","cbt","nt","cdrs-r",1,"clinician",45.25,16.01,16,38.38,11.15,32,33.19,10.86,16,34.94,10.93,32,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,3,0.0625,0.0938,0.0625,0.0938,109,17,6,NA,NA,NA,NA,NA,9.6,NA,NA,46,NA,NA,NA,NA,-0.897655377744697,-0.311594202898551
"179",110,"Weisz, 1997","1997",1,"cbt","cau","cbt","nt","cdi",5,"self-report",18.63,5.32,16,17.81,10.05,32,7.06,6.12,16,11.81,10,32,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,15,0.5,0.4688,0.5,0.4688,110,NA,NA,NA,NA,NA,NA,NA,9.6,NA,NA,46,NA,NA,NA,NA,-2.02272727272727,-0.598503740648379
"180",111,"Weisz, 2009","2009",1,"cbt","cau","cbt","cau","cdi",5,"self-report",10.88,7.91,32,11.29,7.93,25,8,6.32,25,8.47,8.44,19,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,12,10,0.375,0.4,0.48,0.5263,111,NA,NA,NA,NA,NA,NA,NA,11.77,NA,NA,56,NA,NA,NA,NA,-0.404778636683064,-0.344532681734881
"181",112,"Weisz, 2009","2009",1,"cbt","cau","cbt","cau","disc-c MDD symptom count",99,"clinician",10.44,5.27,32,11.33,4.63,24,5.13,3.67,23,6.65,4.64,20,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,9,9,0.2812,0.375,0.3913,0.45,112,13,11,NA,NA,NA,NA,NA,11.77,NA,NA,56,NA,NA,NA,NA,-1.18791946308725,-1.00970873786408
"182",113,"Young, 2006","2005",1,"ipt","other ctr","ipt","school counseling","ces-d",11,"self-report",24.1,6.9,27,27.4,6.6,14,6.4,4.8,27,17.4,10.5,14,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,24,7,0.8889,0.5,0.8889,0.5,113,NA,NA,NA,NA,NA,NA,NA,13.4,NA,NA,85,NA,NA,NA,NA,-3.02564102564103,-1.16959064327485
"183",114,"Young, 2010","2010",1,"ipt","cau","Interpersonal Psychotherapy-Adolescent Skills Training (IPT-AST)","school counseling","ces-d",11,"self-report",NA,NA,NA,NA,NA,NA,NA,NA,36,NA,NA,21,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,114,NA,NA,NA,NA,NA,NA,NA,14.54,NA,NA,59,NA,NA,NA,NA,NA,NA
"184",115,"Young, 2010","2010",1,"ipt","cau","Interpersonal Psychotherapy-Adolescent Skills Training (IPT-AST)","school counseling","cdrs-r",1,"clinician",NA,NA,NA,NA,NA,NA,NA,NA,36,NA,NA,21,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,115,3,2,NA,NA,NA,NA,NA,14.54,NA,NA,59,NA,NA,NA,NA,NA,NA
"185",116,"Young, 2016","2016",1,"ipt","other ctr","Interpersonal Psychotherapy-Adolescent Skills Training (IPT-AST)","group counselling","ces-d",11,"self-report",15.51,8.52,95,15.07,8.65,91,11.12,8.57,93,12.62,9.28,90,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,29,29,0.3053,0.3187,0.3118,0.3222,116,NA,NA,NA,NA,NA,NA,NA,14.01,NA,NA,67,NA,NA,NA,NA,-0.513750731421884,-0.273284997211378
"186",117,"Yu, 2002","2002",1,"cbt","cau","cbt","nt","cdi",5,"self-report",17.44,NA,104,16.72,NA,116,13.64,9.01,101,16.02,10.16,114,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,34,0.2885,0.2931,0.297,0.2982,117,NA,NA,NA,NA,NA,NA,NA,11.8,NA,NA,45,NA,NA,NA,NA,NA,NA
"187",118,"Rohde, 2014a","2014",1,"cbt","other ctr","cognitive behavioral intervention (CB)","educational brochure control","K-SADS (adapted)",6,"clinician",1.37,0.35,126,1.38,0.36,124,1.4,0.32,126,1.5,0.41,124,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,1,0,0.0081,0,0.0081,118,NA,NA,NA,NA,NA,NA,NA,15.5,NA,NA,68,NA,NA,NA,NA,0.0895522388059696,0.311688311688312
"188",119,"Diamond, 2010","2010",1,"other psy","cau","Attachment-Based Family Therapy","enhanced cau","bdi-ii",4,"self-report",33,9.66,35,33,9.37,31,12.6,13.88,35,18.5,15.91,31,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,21,18,0.6,0.5806,0.6,0.5806,119,24,5,NA,NA,NA,NA,NA,15.21,NA,NA,83,NA,NA,NA,NA,-1.73322005097706,-1.14715189873418
"189",120,"Tang, 2009","2009",1,"ipt","cau","Intensive Interpersonal Psychotherapy for depressed adolescents with suicidal risk (IPT-A-IN)","school-based supportive intervention and psychoeducation","bdi-ii",4,"self-report",32.66,10.06,35,32.32,8.7,38,19.97,14.68,35,31.58,12.01,38,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,3,0.4857,0.0789,0.4857,0.0789,120,NA,NA,NA,NA,NA,NA,NA,15.25,NA,NA,66,NA,NA,NA,NA,-1.02586903799515,-0.0714630613230325
"190",121,"Topooco, 2018","2018",1,"cbt","other ctr","cbt","attention control","bdi-ii",4,"self-report",33.1,9.4,33,32.3,10.2,37,19.9,7.2,33,25.2,7.8,37,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,11,2,0.3333,0.0541,0.3333,0.0541,121,NA,NA,NA,NA,NA,NA,NA,17.04,NA,NA,94,NA,NA,NA,NA,-1.59036144578313,-0.788888888888889
"191",122,"Topooco, 2018","2018",1,"cbt","other ctr","cbt","attention control","phq-9",99,"self-report",15.2,4.8,33,14.9,5,37,9.7,2.9,33,10.8,3,37,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,7,2,0.2121,0.0541,0.2121,0.0541,122,38,27,NA,NA,NA,NA,NA,17.04,NA,NA,94,NA,NA,NA,NA,-1.42857142857143,-1.025
"192",123,"Wood, 1996","1996",1,"cbt","other ctr","cbt","relaxing training","mfq",7,"parent_report",25.8,9.8,24,28.7,11.6,24,14.9,10.4,24,19.8,13.3,24,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,15,0.7083,0.625,0.7083,0.625,123,30,26,NA,NA,NA,NA,NA,14.2,NA,NA,69,NA,NA,NA,NA,-1.07920792079208,-0.714859437751004
